Old Web
English
Sign In
Acemap
>
authorDetail
>
Emanuele Noseda
Emanuele Noseda
Novartis
Canakinumab
Medicine
Arthritis
Dosing
Rheumatology
4
Papers
214
Citations
0.00
KQI
Citation Trend
Filter By
Interval:
1900~2024
1900
2024
Author
Papers (4)
Sort By
Default
Most Recent
Most Early
Most Citation
No data
Journal
Conference
Others
Bioequivalence of Canakinumab Liquid Pre-Filled Syringe and Reconstituted Lyophilized Formulations Following 150 mg Subcutaneous Administration: A Randomized Study In Healthy Subjects
2013
Clinical Drug Investigation
Andrea Chioato
Emanuele Noseda
Laurence Colin
Ralph Matott
Andrej Skerjanec
Albert J. Dietz
Show All
Source
Cite
Save
Citations (8)
A Phase II Study to Evaluate Dosing and Preliminary Safety and Efficacy of Canakinumab in Systemic Juvenile Idiopathic Arthritis With Active Systemic Features
2012
Nicolino Ruperto
Pierre Quartier
Nico M. Wulffraat
P Woo
Angelo Ravelli
Richard Mouy
Brigitte Bader-Meunier
Sebastiaan J. Vastert
Emanuele Noseda
Daniele D’Ambrosio
Jean Lecot
Abhijit Chakraborty
Alberto Martini
Andrea Chioato
Show All
Source
Cite
Save
Citations (14)
A phase II, multicenter, open-label study evaluating dosing and preliminary safety and efficacy of canakinumab in systemic juvenile idiopathic arthritis with active systemic features.
2012
Arthritis & Rheumatism
Nicolino Ruperto
Pierre Quartier
Nico Wulffraat
Patricia Woo
Angelo Ravelli
Richard Mouy
Brigitte Bader-Meunier
Sebastiaan J. Vastert
Emanuele Noseda
Daniele D'Ambrosio
Jean Lecot
Abhijit Chakraborty
Alberto Martini
Andrea Chioato
Show All
Source
Cite
Save
Citations (173)
2.2 A phase II trial with canakinumab, a new IL-1beta blocking monoclonal antibody (ACZ885), to evaluate preliminary dosing, safety and efficacy profile in children with systemic Juvenile Idiopathic arthritis (sJIA).
2008
Pediatric Rheumatology
N Ruperto
Pierre Quartier
N Wulffraat
P Woo
Anna Loy
Richard Mouy
Brigitte Bader-Meunier
Berent Prakken
Emanuele Noseda
Christiane Rordorf
Show All
Source
Cite
Save
Citations (19)
1